Neoplasms of the Appendix.
Journal
Deutsches Arzteblatt international
ISSN: 1866-0452
Titre abrégé: Dtsch Arztebl Int
Pays: Germany
ID NLM: 101475967
Informations de publication
Date de publication:
07 08 2023
07 08 2023
Historique:
received:
17
12
2022
revised:
22
05
2023
accepted:
22
05
2023
medline:
19
9
2023
pubmed:
7
6
2023
entrez:
7
6
2023
Statut:
ppublish
Résumé
Neoplasms of the vermiform appendix are rare. They comprise a heterogeneous group of entities requiring differentkinds of treatment. This review is based on publications retrieved by a selective literature search in the PubMed, Embase, and Cochranedatabases. 0.5% of all tumors of the gastrointestinal tract arise in the appendix. Their treatment depends on their histopathologicalclassification and tumor stage. The mucosal epithelium gives rise to adenomas, sessile serrated lesions, adenocarcinomas,goblet-cell adenocarcinomas, and mucinous neoplasms. Neuroendocrine neoplasms originate in neuroectodermal tissue. Adenomasof the appendix can usually be definitively treated by appendectomy. Mucinous neoplasms, depending on their tumorstage, may require additional cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemoperfusion (HIPEC). Adeno -carcinomas and goblet-cell adenocarcinomas can metastasize via the lymphatic vessels and the bloodstream and should thereforebe treated by oncological right hemicolectomy. Approximately 80% of neuroendocrine tumors are less than 1 cm in diameterwhen diagnosed and can therefore be adequately treated by appendectomy; right hemicolectomy is recommended if the patienthas risk factors for metastasis via the lymphatic vessels. Systemic chemotherapy has not been shown to be beneficial forappendiceal neoplasms in prospective, randomized trials; it is recommended for adenocarcinomas and goblet-cell adenocarcinomasof stage III or higher, in analogy to the treatment of colorectal carcinoma.
Sections du résumé
BACKGROUND
Neoplasms of the vermiform appendix are rare. They comprise a heterogeneous group of entities requiring differentkinds of treatment.
METHODS
This review is based on publications retrieved by a selective literature search in the PubMed, Embase, and Cochranedatabases.
RESULTS
0.5% of all tumors of the gastrointestinal tract arise in the appendix. Their treatment depends on their histopathologicalclassification and tumor stage. The mucosal epithelium gives rise to adenomas, sessile serrated lesions, adenocarcinomas,goblet-cell adenocarcinomas, and mucinous neoplasms. Neuroendocrine neoplasms originate in neuroectodermal tissue. Adenomasof the appendix can usually be definitively treated by appendectomy. Mucinous neoplasms, depending on their tumorstage, may require additional cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemoperfusion (HIPEC). Adeno -carcinomas and goblet-cell adenocarcinomas can metastasize via the lymphatic vessels and the bloodstream and should thereforebe treated by oncological right hemicolectomy. Approximately 80% of neuroendocrine tumors are less than 1 cm in diameterwhen diagnosed and can therefore be adequately treated by appendectomy; right hemicolectomy is recommended if the patienthas risk factors for metastasis via the lymphatic vessels. Systemic chemotherapy has not been shown to be beneficial forappendiceal neoplasms in prospective, randomized trials; it is recommended for adenocarcinomas and goblet-cell adenocarcinomasof stage III or higher, in analogy to the treatment of colorectal carcinoma.
Identifiants
pubmed: 37282595
pii: arztebl.m2023.0136
doi: 10.3238/arztebl.m2023.0136
pmc: PMC10534129
doi:
pii:
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
519-525Références
J BUON. 2017 May-Jun;22(3):783-789
pubmed: 28730790
J Trauma Acute Care Surg. 2020 Mar;88(3):396-401
pubmed: 32107355
Arch Pathol Lab Med. 2022 Dec 1;146(12):1471-1478
pubmed: 35472721
J Clin Med. 2022 Aug 02;11(15):
pubmed: 35956110
Front Oncol. 2022 Jul 12;12:915028
pubmed: 35903705
Lancet Oncol. 2023 Feb;24(2):187-194
pubmed: 36640790
Indian J Surg. 2018 Feb;80(1):48-53
pubmed: 29581685
Neuroendocrinology. 2018;106(3):242-251
pubmed: 28641291
Indian J Surg. 2015 Dec;77(Suppl 3):1285-90
pubmed: 27011552
Langenbecks Arch Surg. 2022 Dec;407(8):3615-3622
pubmed: 35962281
Ann Surg Oncol. 2020 Jan;27(1):147-153
pubmed: 31385130
Cancer. 2002 Jun 15;94(12):3307-12
pubmed: 12115365
J Clin Oncol. 2008 Jun 20;26(18):3063-72
pubmed: 18565894
Neuroendocrinology. 2016;103(2):144-52
pubmed: 26730583
Eur J Surg Oncol. 2021 Jan;47(1):11-35
pubmed: 32199769
Br J Surg. 2012 Jul;99(7):987-92
pubmed: 22517234
Endocr Connect. 2018 Feb;7(2):268-277
pubmed: 29335251
Eur J Surg Oncol. 2008 Feb;34(2):196-201
pubmed: 17524597
J Clin Oncol. 2012 Jul 10;30(20):2449-56
pubmed: 22614976
World J Surg Oncol. 2016 Sep 13;14(1):243
pubmed: 27619776
Chirurg. 2019 Mar;90(3):194-201
pubmed: 30456645
Z Gastroenterol. 2018 Jun;56(6):583-681
pubmed: 29890561
Dtsch Arztebl Int. 2019 Nov 1;116(44):739-746
pubmed: 31774053
Ann Surg Oncol. 2020 Dec;27(13):4908-4917
pubmed: 32409962
Am J Surg Pathol. 2016 Jan;40(1):14-26
pubmed: 26492181
Lancet Oncol. 2006 Jan;7(1):69-76
pubmed: 16389186
Ann Surg Oncol. 2017 Jul;24(7):1778-1782
pubmed: 28474197
J Clin Oncol. 2023 Mar 10;41(8):1553-1564
pubmed: 36493333
Endoscopy. 2022 Jan;54(1):16-24
pubmed: 33395714
Ann Surg Oncol. 2022 Dec;29(13):8265-8273
pubmed: 35989392
Acta Gastroenterol Belg. 2020 Jul-Sep;83(3):441-448
pubmed: 33094592
J Surg Oncol. 2014 Jun;109(7):740-5
pubmed: 24375188
J Trauma Acute Care Surg. 2017 Apr;82(4):771-775
pubmed: 28099380
Eur J Surg Oncol. 2015 May;41(5):707-12
pubmed: 25633641
Cancer. 2016 Jan 15;122(2):213-21
pubmed: 26506400